This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The content contained in this program was jointly developed by AMJ, the speakers, and Sanofi and Regeneron, and is not eligible for continuing medical education (CME) credits.
COPD trial outcomes are not all equal, yet conventional endpoints can make it difficult to weigh severe events, exacerbations, lung function, and symptom burden within a single clinical picture. In this AMJ podcast, Sanjay Ramakrishnan and Simon Couillard discuss how win ratio methodology may help capture a broader, more clinically meaningful view of treatment benefit by comparing outcomes across a prespecified hierarchy.
Listen to the full episode to learn:
- Why standard COPD endpoints may not tell the full story
- How win ratio analysis prioritizes outcomes by clinical importance
- What the pooled BOREAS and NOTUS analysis showed
- How this approach could shape future respiratory trial design
Speakers*
Sanjay Ramakrishnan
Simon Couillard
- Clinical Senior Lecturer, UWA Medical School, Centre for Respiratory Health, The University of Western Australia, Perth, Australia
- Professor, Faculty of Medicine and Health, Université de Sherbrooke, Quebec, Canada
*The speakers were compensated by Sanofi and Regeneron in connection with this program.
